CPRIT Product Development Research
Backs CPRIT Product Development Research to support non-dilutive company grants texas cancer therapeutics devices diagnostics new technologies revenue-sharing.
CPRIT Product Development Research provides non-dilutive grant funding (~$70 million per year) to Texas-based companies developing novel cancer treatments, devices, diagnostics, and enabling technologies. Unlike typical state grants, awards are backed by Texas General Obligation bonds and require revenue-sharing agreements (royalties, equity, or other arrangements) back to the state — a royalty-ba…
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.
Funds Texas firms developing cancer diagnostics, companion tools, and biomarkers for clinical deployment.
Funds Texas oncology startups in emerging technologies, including digital and life science manufacturing pathways.
Funds early Texas oncology companies in seed stages while strengthening oncology-specific research development.
Funds Texas oncology companies with revenue-sharing support as therapies move toward commercialization.